BLRX News and Press, BioLineRx Ltd. From 05/25/23

2023-05-25 18:21:14 ET If you’re like many retail traders in the stock market today, penny stocks are a popular prospect. This article looks at some of the most active penny stocks today with late-breaking momentum. They could also be on the radar of traders before next week. But...

2023-05-24 12:15:06 ET BioLineRx Ltd. (BLRX) Q1 2023 Earnings Conference Call May 24, 2023, 10:00 AM ET Company Participants John Lacey - Investor Relations Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commerc...

2023-05-24 07:06:19 ET Biolinerx press release ( NASDAQ: BLRX ): Q1 GAAP EPS of -$0.01 beats by $0.13 . As of March 31, 2023, the company held cash, cash equivalents, and short-term bank deposits of $43.3M and anticipates this will be sufficient to fund operations...

BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) ...

2023-05-23 12:52:36 ET biolinerx ( NASDAQ: BLRX ) is scheduled to announce Q1 earnings results on Wednesday, May 24th, before market open. The consensus EPS Estimate is -$0.14 Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. ...

BioLineRx to Report First Quarter 2023 Results on May 24, 2023 PR Newswire Management to Hold Conference Call at 10:00 a.m. EDT TEL AVIV, Israel , May 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharm...

2023-05-04 13:56:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Most of the biggest biotech stocks on the market started off as unknown penny stocks . Look at Axsome Therapeutics (NASDAQ: AXSM ), for example. At one time, it was a $2.50 ...

2023-04-25 07:36:00 ET Pre-commercial-stage biopharmaceutical company focused on oncology, BioLineRx ( NASDAQ: BLRX ) received formal notice from Nasdaq that the company has regained compliance with the minimum bid price requirement. The company was notified on Novemb...

BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire TEL AVIV, Israel , April 25, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it ...

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma PR Newswire - GENESIS trial achieved statistical significance (p<0.0...